{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for m root_Display\ Name in Display Name (approximate match)
Class (Stereo):
CHEMICAL (ACHIRAL)
BMS-181162, a retinoid derivative, is a phospholipase A2 inhibitor. It was in clinical trials in the treatment of inflammatory diseases, atopic dermatitis, and psoriasis.
Status:
Withdrawn
Source:
Xenazoic acid
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Xenazoic acid, an antiviral agent, was introduced in the early 1960s. Xenazoic acid might be of value in reducing the severity of meals infection if given early enough. Its use was associated with hepatic toxicity, which resulted in its withdrawal from the market in at least two countries (Belgium and France) in 1965. WHO has no information to suggest that xenazoic acid remains commercially available.
Status:
Investigational
Source:
NCT01781559: Not Applicable Interventional Completed Endothelial Dysfunction
(2012)
Source URL:
Class:
MIXTURE
Status:
Other
Class:
MIXTURE
Status:
Other
Class:
MIXTURE
Status:
Other
Class:
MIXTURE
Status:
Other
Class:
MIXTURE
Status:
Other
Class:
MIXTURE
Status:
Other
Class:
MIXTURE
Status:
Other
Class:
MIXTURE
